1. Academic Validation
  2. Optimization of α-amido boronic acids via cryo-electron microscopy analysis: Discovery of a novel highly selective immunoproteasome subunit LMP7 (β5i)/LMP2 (β1i) dual inhibitor

Optimization of α-amido boronic acids via cryo-electron microscopy analysis: Discovery of a novel highly selective immunoproteasome subunit LMP7 (β5i)/LMP2 (β1i) dual inhibitor

  • Bioorg Med Chem. 2024 Jul 15:109:117790. doi: 10.1016/j.bmc.2024.117790.
Yuuki Arai 1 Hiroaki Shitama 2 Masahito Yamagishi 2 Satoshi Ono 2 Akiko Kashima 2 Masahiro Hiraizumi 2 Naoki Tsuda 2 Koushirou Katayama 2 Kouji Tanaka 2 Yuzo Koda 2 Sayuka Kato 2 Kei Sakata 2 Osamu Nureki 3 Hiroshi Miyazaki 4
Affiliations

Affiliations

  • 1 Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan. Electronic address: arai.yuuki@ma.mt-pharma.co.jp.
  • 2 Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan.
  • 3 Department of Biological Sciences, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
  • 4 Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan. Electronic address: miyazaki.hiroshi@me.mt-pharma.co.jp.
Abstract

The immunoproteasome subunit LMP7 (β5i)/LMP2 (β1i) dual blockade has been reported to suppress B cell differentiation and activation, suggesting that the dual inhibition of LMP7/LMP2 is a promising approach for treating autoimmune diseases. In contrast, the inhibition of the constitutive Proteasome subunit β5c correlates with cytotoxicity against non-immune cells. Therefore, LMP7/LMP2 dual inhibitors with high selectivity over β5c may be desirable for treating autoimmune diseases. In this study, we present the optimization and discovery of α-amido boronic acids using cryo-electron microscopy (cryo-EM). The exploitation of structural differences between the Proteasome subunits led to the identification of a highly selective LMP7/LMP2 dual inhibitor 19. Molecular dynamics simulation based on cryo-EM structures of the Proteasome subunits complexed with 19 explained the inhibitory activity profile. In mice immunized with 4-hydroxy-3-nitrophenylacetyl conjugated to ovalbumin, results indicate that 19 is orally bioavailable and shows promise as potential treatment for autoimmune diseases.

Keywords

Autoimmune disease; Constitutive proteasome; Cryo-EM; Immunoproteasome; LMP2; LMP7; β5c.

Figures
Products